{"id":1013880,"date":"2026-10-27T07:05:10","date_gmt":"2026-10-27T11:05:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/"},"modified":"2026-10-27T07:05:10","modified_gmt":"2026-10-27T11:05:10","slug":"adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/","title":{"rendered":"Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO and SUZHOU, China, Oct.  27, 2026  (GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in a fireside chat and one-on-one meetings at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference being held November 9-11, 2026 in Boston, MA.<\/p>\n<p>\n        <strong>Guggenheim Securities 3rd Annual Healthcare Innovation Conference<\/strong><br \/>\n        <br \/>\n        <strong>Format<\/strong>: Fireside Chat and 1&#215;1 Meetings <br \/><strong>Date: <\/strong>November 9, 2026<br \/><strong>Time: <\/strong>9:00 \u2013 9:25 a.m. ET<\/p>\n<p>If you are interested in meeting with\u00a0Adagene\u00a0management during the conference, please reach out to your Guggenheim representative.<\/p>\n<p>A webcast of the fireside chat will be accessible in the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Mkt428MVkHGWMvQhaTRDYuJrRpZYnKFyaS1651ozjarQyYsvTcDiIEigeFUn1mT9vxxW6TWhxnH-z_4WK9NQ-AJdmKfR4Aef-GYO5VfV5ukv9dGR_wU_tvYjq-4abIrUG2yyRkojke1KPJNwYBajq-lMu-G4cGdtmWiOaIxmJEe9yJbfuxQ7BRyjM9uX_ABZflTQQjETeUbFh6M7MhVlyNMMWrZEoKMIg9NhGy15182SH_2oiaw7g8Gjau9bH15t\" rel=\"nofollow\" target=\"_blank\">Investors<\/a>\u00a0section of the Company\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=euHQ_aCMOWOh_UJcmu4tKKNKA97C37L81eCzDO5PsGoaUqbi50C052pHaJlHqdzKilAyO3hGg5zlZOcUb3uL1StQq_1h9ZNq5BGeKWahiY7hNcxt8dBzP9Ks8s7RVHZ6P-A2iHzPb6Nv02ph69NrbWIgOIE7hYlbZWcVsVryu7P0036xJDju-pDAaQMi3FcIti7lbf7gNbxIjG8OPQ6M7uryr088Rig8MKqoVvVci2Zo2z34m6w6VL3S6JG8yqrBqvLvDHW6-x1ezaMFQ51nDA==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.adagene.com<\/a>\u00a0for at least 30 days following the conference.<\/p>\n<p>\n        <strong>About Adagene<\/strong>\n      <\/p>\n<p align=\"justify\">Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody precision masking technology in multiple approaches at the vanguard of science.<\/p>\n<p align=\"justify\">Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody\u2122, SAFEbody, and POWERbody\u2122 technologies, Adagene\u2019s highly differentiated pipeline features novel immunotherapy programs. The company\u2019s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues.<\/p>\n<p align=\"justify\">Adagene\u2019s lead clinical program, muzastotug (ADG126), is a masked anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 on regulatory T cells (Tregs) in the tumor microenvironment. Muzastotug is currently being evaluated in Phase 1b\/2 and Phase 2 clinical studies in combination with anti-PD-1 therapy, particularly in microsatellite stable (MSS) metastatic colorectal cancer (CRC). The FDA has granted Fast Track designation to muzastotug in combination with pembrolizumab for adult patients with MSS metastatic CRC without current or active liver metastases. Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc-empowered antibodies, antibody-drug conjugates, and bispecific and multispecific T-cell engagers.<\/p>\n<p align=\"justify\">For more information, please visit: https:\/\/investor.adagene.com.<br \/>Follow Adagene on WeChat, LinkedIn and X.<\/p>\n<p align=\"justify\">SAFEbody\u00ae is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor Statement<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements, including statements regarding the potential implications of clinical data for patients and Adagene\u2019s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene\u2019s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene\u2019s drug candidates; Adagene\u2019s ability to achieve commercial success for its drug candidates, if approved; Adagene\u2019s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene\u2019s reliance on third parties to conduct drug development, manufacturing and other services; Adagene\u2019s limited operating history and Adagene\u2019s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene\u2019s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, as well as those risks more fully discussed in the \u201cRisk Factors\u201d section in Adagene\u2019s filings with the\u00a0U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to\u00a0Adagene, and\u00a0Adagene\u00a0undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.<\/p>\n<p>\n        <strong>Investor Contacts:<\/strong><br \/>\n        <br \/>Raymond Tam<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tQg2zXytcAucR-zr_QxP1fbkbzTSlcVQrRnJwBsMer063DxB1AqnQ423ktapNdFooTN4iHYvi0yLjccBF75gvm0sUIo2mJaVKIIdccW-J_vrNDyVymohpsmsqnTGIen678lI-qTt_PlVB5WAqoh1nmLrmOrR8_vg0sDYqSaFQWGzvcFSsKLUvZayOAPEH88EECAXsIcvdE5gceYJc417rQEC_UVh1bTSSQP4x9r12LZzO6zzdj-hzHcPKwvNb8tEWmiV8Q78lo6M0I1NxARsj55pPf9PVEp1Ix1-Q-z1MsQ=\" rel=\"nofollow\" target=\"_blank\">Raymond_tam@adagene.com<\/a><br \/>Corey Davis<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pMLAW1T3THze-Y9ZdNOCph2GB7aZ0SwRloeN7pgHdVlVMr4BiGxQVrj3dcByH2xA8D0RdRUM-9SY0A0J20hT3pm_ltNaD4ZOcIKvQPfXQsaMNDqBvvhanMDZnakdbAM6feacargiq1Pwo6umoPW-wTgmmaTE0MU5U0Cblqatm2cxwyvKCbGX4VGRYeuKTtrNdLYp9tTP_aXuLu0R00bnFcc1LuAWoXe1KWVXSHPAAEiio136moQ_sZLpuB_Sg4F6qWi-j9ROqbaL_pmer97Dmg31sXuGQXoTx7zyRI0dBhgAF0ZVQGn8KJv1SwgNsUu9\" rel=\"nofollow\" target=\"_blank\">cdavis@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong>:<br \/>Michael Fitzhugh<br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XmK4duZzqg3qtwSf-0kHogj9q7cTE1Q6-ICIb1j_5O03UAHxSitY6-L8DMKKAtLicOfY-Sy2-nDAQFmxDZ0S56IvO8MrRN6rfD22jBXyXbZ3SqaoWJeQWQBnSCBaW-5V\" rel=\"nofollow\" target=\"_blank\">mfitzhugh@lifescicomms.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTc1MCM3OTEyMjA3IzIyMDQ2ODE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzcxNTgwOGMtMDMxNC00YjE2LWE1MWMtYmJiYWYxZWE4NmI0LTEyMTYyMzQtMjAyNi0xMC0yNy1lbg==\/tiny\/Adagene-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in a fireside chat and one-on-one meetings at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference being held November 9-11, 2026 in Boston, MA. Guggenheim Securities 3rd Annual Healthcare Innovation Conference Format: Fireside Chat and 1&#215;1 Meetings Date: November 9, 2026Time: 9:00 \u2013 9:25 a.m. ET If you are interested in meeting with\u00a0Adagene\u00a0management during the conference, please reach out to your Guggenheim representative. A webcast of the fireside chat will be accessible in the\u00a0Investors\u00a0section of the Company\u2019s website at\u00a0https:\/\/www.adagene.com\u00a0for at least 30 days &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1013880","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in a fireside chat and one-on-one meetings at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference being held November 9-11, 2026 in Boston, MA. Guggenheim Securities 3rd Annual Healthcare Innovation Conference Format: Fireside Chat and 1&#215;1 Meetings Date: November 9, 2026Time: 9:00 \u2013 9:25 a.m. ET If you are interested in meeting with\u00a0Adagene\u00a0management during the conference, please reach out to your Guggenheim representative. A webcast of the fireside chat will be accessible in the\u00a0Investors\u00a0section of the Company\u2019s website at\u00a0https:\/\/www.adagene.com\u00a0for at least 30 days &hellip; Continue reading &quot;Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-27T11:05:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTc1MCM3OTEyMjA3IzIyMDQ2ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference\",\"datePublished\":\"2026-10-27T11:05:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\\\/\"},\"wordCount\":711,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTc1MCM3OTEyMjA3IzIyMDQ2ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\\\/\",\"name\":\"Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTc1MCM3OTEyMjA3IzIyMDQ2ODE=\",\"datePublished\":\"2026-10-27T11:05:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTc1MCM3OTEyMjA3IzIyMDQ2ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTc1MCM3OTEyMjA3IzIyMDQ2ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/","og_locale":"en_US","og_type":"article","og_title":"Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference - Market Newsdesk","og_description":"SAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in a fireside chat and one-on-one meetings at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference being held November 9-11, 2026 in Boston, MA. Guggenheim Securities 3rd Annual Healthcare Innovation Conference Format: Fireside Chat and 1&#215;1 Meetings Date: November 9, 2026Time: 9:00 \u2013 9:25 a.m. ET If you are interested in meeting with\u00a0Adagene\u00a0management during the conference, please reach out to your Guggenheim representative. A webcast of the fireside chat will be accessible in the\u00a0Investors\u00a0section of the Company\u2019s website at\u00a0https:\/\/www.adagene.com\u00a0for at least 30 days &hellip; Continue reading \"Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-27T11:05:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTc1MCM3OTEyMjA3IzIyMDQ2ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference","datePublished":"2026-10-27T11:05:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/"},"wordCount":711,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTc1MCM3OTEyMjA3IzIyMDQ2ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/","name":"Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTc1MCM3OTEyMjA3IzIyMDQ2ODE=","datePublished":"2026-10-27T11:05:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTc1MCM3OTEyMjA3IzIyMDQ2ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTc1MCM3OTEyMjA3IzIyMDQ2ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1013880"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013880\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1013880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1013880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1013880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}